Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss
1 other identifier
interventional
60
1 country
2
Brief Summary
Assessing the efficiency of Prophylactic use of local tranexamic acid during vaginal hysterectomy to reduce blood loss during operation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2021
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 16, 2021
CompletedStudy Start
First participant enrolled
February 16, 2021
CompletedFirst Posted
Study publicly available on registry
February 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedMay 6, 2025
May 1, 2025
4.4 years
February 16, 2021
May 1, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Blood loss during operation - measure in ml
At the end of the surgery, surgeon will measure the blood in the suction can
End of surgery
Study Arms (2)
local tranexamic acid injection to cervix
EXPERIMENTAL1 gr of Tranexamic acid diluted in 10 ml saline
local normal saline injection to cervix
PLACEBO COMPARATOR20 ml of saline
Interventions
local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
local normal saline injection to the cervix- 20 ml saline
Eligibility Criteria
You may qualify if:
- years old female patients going through vaginal hysterctomy
You may not qualify if:
- massive bleeding during operation due to major vessles injury
- known coagulopathies
- sensitivity to tranexamic acid
- medical need in tranexamic acid administration during operation due to bleeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Meir Medical Center
Kfar Saba, Israel, 11125, Israel
Meir medical center
Kfar Saba, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 16, 2021
First Posted
February 18, 2021
Study Start
February 16, 2021
Primary Completion
July 1, 2025
Study Completion (Estimated)
June 1, 2026
Last Updated
May 6, 2025
Record last verified: 2025-05